TR200002824T2 - TNF reseptörü üst-ailesinin bir unsuru olan gelişmiş FLINT (mFLINT) polipeptitlerin veya OPG3'ün tedavi amaçlı uygulamaları. - Google Patents

TNF reseptörü üst-ailesinin bir unsuru olan gelişmiş FLINT (mFLINT) polipeptitlerin veya OPG3'ün tedavi amaçlı uygulamaları.

Info

Publication number
TR200002824T2
TR200002824T2 TR2000/02824T TR200002824T TR200002824T2 TR 200002824 T2 TR200002824 T2 TR 200002824T2 TR 2000/02824 T TR2000/02824 T TR 2000/02824T TR 200002824 T TR200002824 T TR 200002824T TR 200002824 T2 TR200002824 T2 TR 200002824T2
Authority
TR
Turkey
Prior art keywords
flint
mflint
advanced
opg3
polypeptides
Prior art date
Application number
TR2000/02824T
Other languages
English (en)
Inventor
Frank Bumol Thomas
Dou Shenshen
Lawrence Glasebrook Andrew
Elliot Gould Kenneth
Edward Hale John
Georg Heuer Josef
Yuk Hui Kwan
Kharitonenkov Alexei
Mizrahi Jacques
Na Songqing
Wayne Noblitt Timothy
Arthur Reidy Charles
Yeong Song Ho
Wang Jian
Wu Xiying
Harold Zuckerman Steven
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of TR200002824T2 publication Critical patent/TR200002824T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Gelismis FLINT proteini (mFLINT) FasL ve LIGHT'ye baglanir ve FasL-Fas etkilesimini önler. mFLINT FasL-Fas vasitasiyla ortaya çikan apoptotik ve pro-enflamatuvar etkinligi önler ve anormal apoptoz ve enflamasyon ile iliskilendirilen bozukluklarin tedavisinde faydalidir. Bulus FLINT ve yetiskin FLINT'e ait olan amino asitleri ve nükleotid dizilerini tedarik etmistir. FLINT ifade eden transjenik hayvanlarin hazirlanmasi ve hususiyetleri ve ayrica mFLINT kullanilan, tedaviye yönelik bilesimler ve tedavi yöntemleri de ayrica bulus içinde kapsanmistir.
TR2000/02824T 1998-03-30 1999-03-30 TNF reseptörü üst-ailesinin bir unsuru olan gelişmiş FLINT (mFLINT) polipeptitlerin veya OPG3'ün tedavi amaçlı uygulamaları. TR200002824T2 (tr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US7985698P 1998-03-30 1998-03-30
US8607498P 1998-05-20 1998-05-20
US9964398P 1998-09-09 1998-09-09
US11257798P 1998-12-17 1998-12-17
US11270398P 1998-12-18 1998-12-18
US11293398P 1998-12-18 1998-12-18
US11340798P 1998-12-22 1998-12-22

Publications (1)

Publication Number Publication Date
TR200002824T2 true TR200002824T2 (tr) 2000-12-21

Family

ID=27568394

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/02824T TR200002824T2 (tr) 1998-03-30 1999-03-30 TNF reseptörü üst-ailesinin bir unsuru olan gelişmiş FLINT (mFLINT) polipeptitlerin veya OPG3'ün tedavi amaçlı uygulamaları.

Country Status (16)

Country Link
US (1) US20040167074A1 (tr)
JP (1) JP2002512006A (tr)
KR (1) KR20010042364A (tr)
CN (1) CN1303429A (tr)
AU (1) AU3369199A (tr)
BR (1) BR9909328A (tr)
CA (1) CA2324517A1 (tr)
CZ (1) CZ20003433A3 (tr)
EA (1) EA200001004A1 (tr)
HU (1) HUP0102067A2 (tr)
ID (1) ID27820A (tr)
IL (1) IL138626A0 (tr)
NO (1) NO20004873L (tr)
PL (1) PL343847A1 (tr)
TR (1) TR200002824T2 (tr)
WO (1) WO1999050413A2 (tr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
KR20000070174A (ko) 1997-01-14 2000-11-25 벤슨 로버트 에이치. 종양 괴사 인자 수용체 6α 및 6β
WO1999014330A1 (en) 1997-09-18 1999-03-25 Genentech, Inc. DcR3 POLYPEPTIDE, A TNFR HOMOLOG
AU2211100A (en) * 1998-12-22 2000-07-12 Eli Lilly And Company Therapeutic applications of flint polypeptides
EP1165781B1 (en) * 1999-03-30 2007-08-29 Eli Lilly And Company Protease resistant flint analogs
US6627199B1 (en) 1999-07-09 2003-09-30 Amgen Inc Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family
AU6517800A (en) * 1999-08-04 2001-03-05 Amgen, Inc. Ntr3, a member of the tnf-receptor supergene family
AU783682B2 (en) 1999-08-04 2005-11-24 Amgen, Inc. Fhm, a novel member of the TNF ligand supergene family
WO2001018041A2 (en) * 1999-09-10 2001-03-15 Eli Lilly And Company Flint proteins and formulations thereof
EP1225908A2 (en) * 1999-10-20 2002-07-31 Eli Lilly And Company Therapeutic applications of flint polypeptides
AU1915201A (en) * 1999-12-07 2001-06-18 Eli Lilly And Company Improving stability of flint through o-linked glycosylation
AU2001286688A1 (en) * 2000-08-25 2002-03-13 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6alpha and 6beta
WO2002066050A1 (en) * 2001-02-23 2002-08-29 Takeda Chemical Industries, Ltd. Casoase 3 inhibitors
CA2520138C (en) 2003-03-26 2017-05-23 Apogenix Gmbh Improved fc fusion proteins
EP1841442A4 (en) * 2005-01-07 2009-12-09 Northern Sydney And Central Co TREATMENT OF AUTOIMMUNE DISEASES AND INFLAMMATORY DISEASES
ES2523992T3 (es) 2006-12-28 2014-12-03 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts La neutralización de la actividad de CD95 bloquea la invasión de células de glioblastoma in vivo
US20110189194A1 (en) * 2008-07-14 2011-08-04 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Use of cd95 inhibitors for the treatment of inflammatory disorders
CN102671186B (zh) * 2011-09-19 2014-08-06 上海市肿瘤研究所 促造血的药物组合物及其应用
RU2652348C2 (ru) 2012-07-18 2018-04-25 Аподжиникс Аг Ингибиторы сигнального пути cd95 для лечения мдс
EP3076179A1 (en) 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnosis and treatment of low grade gliomas
JP6876066B2 (ja) 2015-12-18 2021-05-26 タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 子宮膣部びらんを予防及び治療するための方法
WO2017101873A1 (zh) * 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗放射性和化学性损伤的方法
CA3134144A1 (en) 2019-03-29 2020-10-08 Myst Therapeutics, Llc Ex vivo methods for producing a t cell therapeutic and related compositions and methods
CA3162703A1 (en) 2019-11-27 2021-06-03 Myst Therapeutics, Llc Method of producing tumor-reactive t cell composition using modulatory agents
JP7817937B2 (ja) 2020-02-27 2026-02-19 ターンストーン バイオロジクス コーポレイション 腫瘍反応性ｔ細胞のエクスビボ富化および増大のための方法ならびに関連するその組成物
WO2026044087A1 (en) 2024-08-21 2026-02-26 Shape Therapeutics Inc. Increased cellular stability for aav production
WO2026073032A1 (en) 2024-09-27 2026-04-02 Shape Therapeutics Inc. Constructs for improved aav production

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000070174A (ko) * 1997-01-14 2000-11-25 벤슨 로버트 에이치. 종양 괴사 인자 수용체 6α 및 6β
US5885800A (en) * 1997-02-04 1999-03-23 Smithkline Beecham Corporation DNA encoding tumor necrosis related receptor, TR4
WO1999004001A1 (en) * 1997-07-21 1999-01-28 Zymogenetics, Inc. Tumor necrosis factor receptor ztnfr-5
JP2001512667A (ja) * 1997-08-06 2001-08-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトオーファンレセプターｎｔｒ−１
WO1999014330A1 (en) * 1997-09-18 1999-03-25 Genentech, Inc. DcR3 POLYPEPTIDE, A TNFR HOMOLOG
WO1999026977A1 (en) * 1997-11-24 1999-06-03 Biogen, Inc. Novel receptors opg-2

Also Published As

Publication number Publication date
PL343847A1 (en) 2001-09-10
AU3369199A (en) 1999-10-18
WO1999050413A2 (en) 1999-10-07
HUP0102067A2 (hu) 2001-10-28
EA200001004A1 (ru) 2001-06-25
CA2324517A1 (en) 1999-10-07
NO20004873D0 (no) 2000-09-28
CN1303429A (zh) 2001-07-11
WO1999050413A3 (en) 1999-12-02
BR9909328A (pt) 2000-12-12
JP2002512006A (ja) 2002-04-23
IL138626A0 (en) 2001-10-31
NO20004873L (no) 2000-11-24
KR20010042364A (ko) 2001-05-25
US20040167074A1 (en) 2004-08-26
CZ20003433A3 (cs) 2001-10-17
ID27820A (id) 2001-04-26

Similar Documents

Publication Publication Date Title
TR200002824T2 (tr) TNF reseptörü üst-ailesinin bir unsuru olan gelişmiş FLINT (mFLINT) polipeptitlerin veya OPG3'ün tedavi amaçlı uygulamaları.
US20240059751A1 (en) Interleukin-2 variants and methods of uses thereof
KR101013401B1 (ko) 신규 시토카인 ｚｃｙｔｏｒ17 리간드
ES2281126T3 (es) Receptor 5 que contiene un dominio de muerte.
Götz et al. Neurotrophin-6 is a new member of the nerve growth factor family
ES2284199T3 (es) Receptor 4 que contiene dominio de muerte (dr4:receptor 4 de muerte), miembro de la superfamilia de receptores tnf y union a trail (apo-2l).
AU2020292421A1 (en) Novel interleukin-2 variants and bifunctional fusion molecules thereof
ES2287950T3 (es) Proteina receptora designada 2f1.
PT1132403E (pt) Peptidos inibidores de tgf g beta1
TR200003113T2 (tr) 3-(amino- veya aminoalkil) piridinon türevleri ve bunların HIV bağımlı hastalıkların tedavisinde kullanılması.
EE200100006A (et) Bifenüülsulfoonamiidid kui duaalse angiotensiin-endoteliini retseptori antagonistid
DE60028830D1 (de) Anti-april antikörper und hybridomazellen
DK1260521T3 (da) Immunoglobulinvarianter af specifikke Fc-epsilonreceptorer
EA200000911A1 (ru) Новые кристаллические формы антивирусного соединения бензимидазола
MA31040B1 (fr) Anticorps anti-cd20 avec une augmentation de l'affinite de fixation sur le recepteur fc et de la fonction effectrice.
TR200200912T2 (tr) APRIL (çoğalma uyarıcı ligand) reseptörü (BCMA) ve kullanımları
EP1100535A4 (en) Targeting pharmaceutical agents to injured tissues
DE60045681D1 (de) Vaskuläre adhesionsmoleküle und modulierung ihrer funktion
NO991926D0 (no) Oppl°selige lymfotoksin-<beta> reseptorer, anti-lymfotoksinreseptor antistoff samt anti-lymfotoksin-ligand antistoff som terapeutiske midler til behandling av immunologiske sykdommer
ES2252786T3 (es) Muteinas de interleucina-4 de alta afinidad.
TR200000610T2 (tr) IL-8 reseptör karşıtları.
EP1456239A4 (en) HYBRID PROTEINS FACED WITH HEPARANSULFATE PROTEOGLYCANE WITH NEUREGULIN-HEPARIN BINDING DOMAIN
ATE285772T1 (de) Verwendung von indol-2,3-dione-3-oximderivate als ampa-antagonisten
TR200102655T2 (tr) Dört L. infantum proteininin antijen belirleyicilerini kodlayan kimerik gen.
DE69831223D1 (de) Gefriergetrocknete zusammensetzung des menschlichen,morphogenen knochenproteins mp52